Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611txm

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 16:43:53 ON 19 OCT 2005
FILE 'REGISTRY' ENTERED AT 16:43:53 ON 19 OCT 2005
COPYRIGHT (C) 2005 American Chemical Society (ACS)
=> file reg
FILE 'REGISTRY' ENTERED AT 16:44:01 ON 19 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 18 OCT 2005 HIGHEST RN 865529-02-8
DICTIONARY FILE UPDATES: 18 OCT 2005 HIGHEST RN 865529-02-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10751703.str



chain nodes :
17 18 20 21 23 24 25
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 27
chain bonds :
2-27 8-12 9-17 10-18 11-25 13-20 14-21 15-23 16-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16
exact/norm bonds :
2-27 5-7 6-10 7-8 8-9 9-17 9-10 10-18 11-25 13-20 14-21 15-23 16-24
exact bonds :
8-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

G1:H,X

G2:CH3,Et

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 20:CLASS
21:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 16:44:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 29 TO ITERATE

100.0% PROCESSED 29 ITERATIONS 16 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 257 TO 903
PROJECTED ANSWERS: 80 TO 560

L2 16 SEA SSS SAM L1

=> d scan

L2 16 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[(cis-4-hydroxy-4-methylcyclohexyl)amino]-8-methyl-, monohydrochloride (9CI)
MF C21 H23 Cl N4 O2 . Cl H

Relative stereochemistry.



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 16 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-8-methyl- (9CI)
MF C24 H22 Cl2 N4 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 16 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Phosphonic acid, [[[[4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]methyl]hydroxyphosphinyl]methyl]- (9CI)
MF C22 H20 Cl2 N4 O6 P2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 16 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-methyl-6-phenyl-2-(phenylamino)- (9CI)
MF C20 H16 N4 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 16 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 4-Piperidinamine, N-[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-1-[(1-methylethyl)sulfonyl]- (9CI)
MF C22 H26 Cl N5 O3 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full; file caplus; s l3; s wo-20040063195?/pn
FULL SEARCH INITIATED 16:45:38 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 623 TO ITERATE

100.0% PROCESSED 623 ITERATIONS 314 ANSWERS
SEARCH TIME: 00.00.01

L3 314 SEA SSS FUL L1

FILE 'CAPLUS' ENTERED AT 16:45:39 ON 19 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Oct 2005 VOL 143 ISS 17
FILE LAST UPDATED: 18 Oct 2005 (20051018/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

L4 67 L3

L5 1 WO-20040063195?/PN

(WO2004063195/PN)

```
=> s l4 not l5
L6          66 L4 NOT L5

=> s wo-20010044258/pn
L7           1 WO-20010044258/PN
                (WO2001044258/PN)

=> s l6 and l7
L8           1 L6 AND L7

=> d cbib pi hitstr

L8   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
2001:453076   Document No. 135:46047  Preparation of pyrimidine heterocycles
     with a phosphorus containing moiety for pharmaceutical use in the
     treatment of bone disorders.  Weigele, Manfred; Dalgarno, David C.; Luke,
     George P.; Sawyer, Tomi K.; Bohacek, Regine; Shakespeare, William C.;
     Sundaramoorthi, Rajeswari; Wang, Yihan; Metcalf, Chester A., III; Vu, Chi
     B.; Kawahata, Noriyuki H. (Ariad Pharmaceuticals, Inc., USA).  PCT Int.
     Appl. WO 2001044258 A1 20010621, 186 pp.  DESIGNATED STATES: W:  AE, AG,
     AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE,
     DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
     KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
     MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
     TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM;
     RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB,
     GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.  (English).
     CODEN: PIXXD2.  APPLICATION: WO 2000-US34487 20001218.  PRIORITY: US
     1999-PV172510 19991217; US 1999-PV172161 19991217; US 2000-PV240788
     20001016; US 2000-741619 20001218; US 2000-740653 20001218.
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     ----------------    ----   --------    --------------------     --------
PI   WO 2001044258         A1    20010621    WO 2000-US34487          20001218 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
             YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2394650             AA    20010621    CA 2000-2394650          20001218
     AU 2001024397          A5    20010625    AU 2001-24397            20001218
     US 2002132819          A1    20020919    US 2000-740653           20001218
     EP 1246829             A1    20021009    EP 2000-988160           20001218
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2003532632          T2    20031105    JP 2001-544748           20001218
     US 2005096298          A1    20050505    US 2004-994962           20041122
IT   344891-17-4P 344891-23-2P 344891-24-3P
     344891-26-5P 344891-28-7P
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
     BIOL (Biological study); PREP (Preparation); USES (Uses)
        (preparation of pyrimidine heterocycles with a phosphorus containing moiety
for
```

pharmaceutical use in the treatment of bone disorders)

RN 344891-17-4 CAPLUS

CN Phosphonic acid, [[4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]methylene]bis- (9CI) (CA INDEX NAME)



RN 344891-23-2 CAPLUS

CN Phosphonic acid, [5-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-2-hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 344891-24-3 CAPLUS

CN 2,6-Pyridinedicarboxylic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 344891-26-5 CAPLUS

CN Phosphonic acid, [5-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 344891-28-7 CAPLUS
CN Phosphonic acid, [[[4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]hydroxyphosphinyl]methyl]- (9CI) (CA INDEX NAME)



IT **344891-43-6P 344891-47-0P 344891-69-6P**
344891-70-9P 344891-71-0P 344891-72-1P
344891-73-2P 344891-74-3P 344891-75-4P
344891-79-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine heterocycles with a phosphorus containing moiety for
pharmaceutical use in the treatment of bone disorders)
RN 344891-43-6 CAPLUS
CN Phosphonic acid, [[[4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]ethoxyphosphinyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 344891-47-0 CAPLUS
CN Phosphonic acid, [[4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]methylene]bis-, tetraethyl ester (9CI) (CA INDEX NAME)



RN 344891-69-6 CAPLUS
CN Phosphonic acid, [5-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-2-(phenylmethoxy)phenyl]-, diethyl ester (9CI) (CA INDEX NAME)



RN 344891-70-9 CAPLUS
CN Phosphonic acid, [5-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-2-hydroxyphenyl]-, diethyl ester

(9CI) (CA INDEX NAME)



RN 344891-71-0 CAPLUS
CN Methanesulfonic acid, trifluoro-, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-2-(diethoxyphosphinyl)phenyl ester (9CI) (CA INDEX NAME)



RN 344891-72-1 CAPLUS
CN Phosphonic acid, [4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-1,2-phenylene]bis-, tetraethyl ester (9CI) (CA INDEX NAME)



RN 344891-73-2 CAPLUS
CN Acetic acid, [4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-2-phosphonophenoxy]-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 344891-74-3 CAPLUS
CN Acetic acid, [4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-2-(diethoxyphosphinyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 344891-75-4 CAPLUS
CN 2,6-Pyridinedicarboxylic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, diethyl ester (9CI) (CA INDEX NAME)



RN 344891-79-8 CAPLUS
CN Phosphonic acid, [5-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-2-pyridinyl]-, diethyl ester (9CI) (CA INDEX NAME)



=> s wo-20030057165?/pn
L9 1 WO-20030057165?/PN
(WO2003057165/PN)

=> s l6 and l9
L10 1 L6 AND L9

=> d cbib pi hitstr

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2005 ACS on STN
2003:551338 Document No. 139:111702 Compositions and methods using ATP-dependent γ-secretase modulators for prevention and treatment of amyloid-β peptide-related disorders, and screening methods for modulators of Aβ. Netzer, William J.; Greengard, Paul; Xu, Huaxi (The Rockefeller University, USA). PCT Int. Appl. WO 2003057165 A2 20030717, 142 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL,

PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US249 20030106. PRIORITY: US 2002-2002/PV345009 20020104.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003057165	A2	20030717	WO 2003-US249	20030106 <--
	WO 2003057165	A3	20031113		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2004028673	A1	20040212	US 2003-337261	20030106
	EP 1469810	A2	20041027	EP 2003-703695	20030106
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005522417	T2	20050728	JP 2003-557524	20030106

IT **185039-91-2 185039-91-2D**, derivs. **260415-63-2 260415-63-2D**, derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ATP-dependent enzyme modulators for prevention and treatment of amyloid-β peptide-related disorders, and screening methods for modulators of Aβ)

RN 185039-91-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



1-4
6-8
10
12-16
21

RN 185039-91-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)

197
18
19
23



RN 260415-63-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 260415-63-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)



```
=> s us-5945422/pn
L11           1 US-5945422/PN
                (US5945422/PN)

=> s l11 and l6
L12           1 L11 AND L6

=> d cbib pi hitstr

L12  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2005 ACS on STN
```

1999:561587 Document No. 131:184962 Preparation of oxidoamino-substituted pyrido[2,3-d]pyrimidines as protein tyrosine kinase inhibitors. Doherty, Annette Marian; Hallak, Hussein Osman; Hamby, James Marino (Warner-Lambert Company, USA). U.S. US 5945422 A 19990831, 25 pp. (English). CODEN: USXXAM. APPLICATION: US 1998-15739 19980129. PRIORITY: US 1997-38822 19970205.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5945422	A	19990831	US 1998-15739	19980129 <--

IT **212391-66-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxidoamino-substituted pyrido[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)

RN 212391-66-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethyloxidoamino)ethoxy]phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



IT **185039-27-4P 185039-31-0P 185039-47-8P**
185039-55-8P 185039-56-9P 185039-58-1P
185039-59-2P 185039-60-5P 185039-61-6P
185039-68-3P 185039-79-6P 185039-80-9P
185039-88-7P 185039-89-8P 205115-81-7P

16

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxidoamino-substituted pyrido[2,3-d]pyrimidines as protein tyrosine kinase inhibitors)

RN 185039-27-4 CAPLUS

CN Butanoic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 185039-31-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(diethylamino)propyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



28, 29

RN 185039-47-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-55-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-56-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(4-morpholinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-58-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-59-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-60-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-61-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-68-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[4-(4-methyl-1-piperazinyl)butyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-79-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-80-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(2-methoxyphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



1, 3, 4
6-15
23, 24

RN 185039-88-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(3-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 185039-89-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



18

RN 205115-81-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(4-pyridinylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

=> s us-5733914?/pn
L13 2 US-5733914?/PN
(US5733914?/PN)

=> s l6 and l13
L14 2 L6 AND L13

=> d cbib pi hitstr 1-2

L14 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
1998:202673 Document No. 128:257440 Preparation of pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation. Blankley, Clifton John; Boschelli, Diane Harris; Doherty, Annette Marian; Hamby, James Marino; Klutchko, Sylvester; Panek, Robert Lee (Warner-Lambert Company, USA). U.S. US 5733914 A 19980331, 39 pp., Cont.-in-part of U.S. 5,620,981. (English). CODEN: USXXAM. APPLICATION: US 1996-611279 19960403. PRIORITY: US 1995-433294 19950503.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5733914	A	19980331	US 1996-611279	19960403 <--
	US 5620981	A	19970415	US 1995-433294	19950503
	IL 117923	A1	20000601	IL 1996-117923	19960416
	CA 2214219	AA	19961107	CA 1996-2214219	19960426

(e)

WO 9634867		A1	19961107	WO 1996-US5819	19960426
W:	AU, BG, CA, CN, CZ, EE, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9655769		A1	19961121	AU 1996-55769	19960426
AU 713727		B2	19991209		
EP 823908		A1	19980218	EP 1996-913175	19960426
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1183099		A	19980527	CN 1996-193678	19960426
CN 1083452		B	20020424		
JP 11504922		T2	19990511	JP 1996-533372	19960426
NZ 307021		A	20010427	NZ 1996-307021	19960426
CZ 288160		B6	20010516	CZ 1997-3275	19960426
EE 3770		B1	20020617	EE 1997-274	19960426
PL 184093		B1	20020830	PL 1996-323089	19960426
SK 283952		B6	20040608	SK 1997-1410	19960426
ZA 9603486		A	19961113	ZA 1996-3486	19960502
NO 9705033		A	19971031	NO 1997-5033	19971031
NO 310110		B1	20010521		

IT **185039-70-7P 185039-83-2P 185039-93-4P 185039-98-9P 185040-00-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation)

RN 185039-70-7 CAPLUS

CN Hexanoic acid, 6-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 185039-83-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-93-4 CAPLUS
CN Benzeneacetic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 185039-98-9 CAPLUS
CN Benzoic acid, 3-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 185040-00-0 CAPLUS
CN Benzenebutanoic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



IT **185039-26-3P 185039-27-4P 185039-28-5P**
185039-31-0P 185039-47-8P 185039-49-0P
185039-51-4P 185039-52-5P 185039-53-6P
185039-54-7P 185039-55-8P 185039-56-9P
185039-57-0P 185039-58-1P 185039-59-2P
185039-60-5P 185039-63-8P 185039-64-9P
185039-65-0P 185039-66-1P 185039-67-2P
185039-68-3P 185039-69-4P 185039-71-8P
185039-72-9P 185039-73-0P 185039-78-5P
185039-79-6P 185039-80-9P 185039-81-0P
185039-82-1P 185039-84-3P 185039-85-4P
185039-86-5P 185039-87-6P 185039-88-7P
185039-89-8P 185039-90-1P 185039-91-2P
185039-92-3P 185039-94-5P 185039-95-6P
185039-96-7P 185039-97-8P 185039-99-0P
185040-01-1P 185040-02-2P 185040-07-7P
185040-17-9P 205115-79-3P 205115-80-6P
205115-81-7P 205115-82-8P 205115-84-0P
205115-87-3P 205115-88-4P 205115-89-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation)

RN 185039-26-3 CAPLUS

CN Acetamide, N-[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 185039-27-4 CAPLUS

CN Butanoic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 185039-28-5 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 185039-31-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(diethylamino)propyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



24
25

RN 185039-47-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-49-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(methylamino)- (9CI) (CA INDEX NAME)



RN 185039-51-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-(ethylamino)-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-52-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(2-hydroxyethyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-53-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-54-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-(butylamino)-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-55-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-56-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(4-morpholinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-57-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-58-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-59-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-60-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-63-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



1, 3, 4, 6-8

10-14 54

18 23 36-54/38

21

RN 185039-64-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-[(3-bromophenyl)amino]-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



103-19

1-53

55 56/38 to 9/38

RN 185039-65-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-[(4-chlorophenyl)amino]-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-66-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-(1,3-benzodioxol-5-ylamino)-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-67-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 185039-68-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[4-(4-methyl-1-piperazinyl)butyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-69-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-(cyclohexylamino)-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



2 pages 36-54/40 Ex 60

RN 185039-71-8 CAPLUS
CN Hexanoic acid, 6-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 185039-72-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(4-methylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-73-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-methoxyphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-78-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



RN 185039-79-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-80-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(2-methoxyphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-81-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(3-methoxyphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-82-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-methoxy-3-methylphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-84-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-[(4-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-85-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-ethoxyphenyl)amino]-8-ethyl- (9CI) (CA INDEX NAME)



RN 185039-86-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(3,4-dimethoxyphenyl)amino]-8-ethyl- (9CI) (CA INDEX NAME)



RN 185039-87-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-[(3,4,5-trimethoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-88-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(3-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 185039-89-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-90-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[5-(4-methyl-1-piperazinyl)pentyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-91-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-92-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(3,5-dimethoxyphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-94-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(6-methoxy-3-pyridinyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



9

RN 185039-95-6 CAPLUS
CN Benzeneacetic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 185039-96-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(3-hydroxyphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



2

1,3,4 87
6-8 41-60/45
10, 12-14
21

RN 185039-97-8 CAPLUS
CN Benzoic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

1-4
6-10
18, 21, 23
25



RN 185039-99-0 CAPLUS
CN Benzoic acid, 3-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 185040-01-1 CAPLUS
CN Benzenebutanoic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 185040-02-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 185040-07-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-bromo-6-chlorophenyl)-8-ethyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



RN 185040-17-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-ethyl-6-phenyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



RN 205115-79-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 205115-80-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-[4-(4-methoxyphenyl)-1-piperazinyl]propyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 205115-81-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(4-pyridinylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 205115-82-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-[(4-hydroxyphenyl)amino]-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 205115-84-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-(4-pyridinylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 205115-87-3 CAPLUS
CN Hexanoic acid, 6-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 185039-71-8
CMF C20 H20 Cl2 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 205115-88-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-bromo-6-chlorophenyl)-8-ethyl-2-(phenylamino)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 205115-89-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-ethyl-6-phenyl-2-(phenylamino)-, hydrochloride (2:1) (9CI) (CA INDEX NAME)



●1/2 HCl

L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
1997:26258 Document No. 126:59965 Preparation of pyrido[2,3-d]pyrimidines as protein tyrosine kinase mediated cell proliferation inhibitors. Blankley, Clifton John; Boschelli, Diane Harris; Doherty, Annette Marian; Hamby, James Marino; Klutchko, Sylvester; Panek, Robert Lee (Warner-Lambert Company, USA). PCT Int. Appl. WO 9634867 A1 19961107, 147 pp. DESIGNATED STATES: W: AU, BG, CA, CN, CZ, EE, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English). CODEN: PIXXD2. APPLICATION: WO 1996-US5819 19960426. PRIORITY: US 1995-433294 19950503; US 1996-611279 19960403.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9634867	A1	19961107	WO 1996-US5819	19960426	
	W: AU, BG, CA, CN, CZ, EE, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	US 5620981	A	19970415	US 1995-433294	19950503	
	US 5733914	A	19980331	US 1996-611279	19960403	<--
	AU 9655769	A1	19961121	AU 1996-55769	19960426	
	AU 713727	B2	19991209			
	EP 823908	A1	19980218	EP 1996-913175	19960426	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI					
	JP 11504922	T2	19990511	JP 1996-533372	19960426	
	NZ 307021	A	20010427	NZ 1996-307021	19960426	
	EE 3770	B1	20020617	EE 1997-274	19960426	
	PL 184093	B1	20020830	PL 1996-323089	19960426	
	SK 283952	B6	20040608	SK 1997-1410	19960426	
	NO 9705033	A	19971031	NO 1997-5033	19971031	
	NO 310110	B1	20010521			

IT **185039-26-3P 185039-27-4P 185039-28-5P**
185039-31-0P 185039-47-8P 185039-49-0P
185039-51-4P 185039-52-5P 185039-53-6P
185039-54-7P 185039-55-8P 185039-56-9P
185039-57-0P 185039-58-1P 185039-59-2P
185039-60-5P 185039-61-6P 185039-63-8P
185039-64-9P 185039-65-0P 185039-66-1P
185039-67-2P 185039-68-3P 185039-69-4P
185039-70-7P 185039-71-8P 185039-72-9P
185039-73-0P 185039-78-5P 185039-79-6P
185039-80-9P 185039-81-0P 185039-82-1P
185039-83-2P 185039-84-3P 185039-85-4P

185039-86-5P 185039-87-6P 185039-88-7P
185039-89-8P 185039-90-1P 185039-91-2P
185039-92-3P 185039-93-4P 185039-94-5P
185039-95-6P 185039-96-7P 185039-97-8P
185039-98-9P 185039-99-0P 185040-00-0P
185040-01-1P 185040-02-2P 185040-07-7P
185040-17-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrido[2,3-d]pyrimidines as protein tyrosine kinase mediated cell proliferation inhibitors)

RN 185039-26-3 CAPLUS
CN Acetamide, N-[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 185039-27-4 CAPLUS
CN Butanoic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-4-oxo- (9CI) (CA INDEX NAME)



RN 185039-28-5 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)



RN 185039-31-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(diethylamino)propyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-47-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-49-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(methylamino)- (9CI) (CA INDEX NAME)



RN 185039-51-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-(ethylamino)-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-52-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(2-hydroxyethyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-53-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-54-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-(butylamino)-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-55-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-56-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(4-morpholinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-57-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-58-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(2-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-59-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(3-pyridinylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-60-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[2-(2-pyridinyl)ethyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-61-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-63-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



RN 185039-64-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-[(3-bromophenyl)amino]-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-65-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-[(4-chlorophenyl)amino]-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-66-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-(1,3-benzodioxol-5-ylamino)-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-67-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 185039-68-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[4-(4-methyl-1-piperazinyl)butyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-69-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-(cyclohexylamino)-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-70-7 CAPLUS
CN Hexanoic acid, 6-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 185039-71-8 CAPLUS
CN Hexanoic acid, 6-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 185039-72-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[(4-methylphenyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-73-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-methoxyphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-78-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



RN 185039-79-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-80-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(2-methoxyphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-81-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(3-methoxyphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-82-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-methoxy-3-methylphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-83-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-[(4-methoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-84-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-[(4-hydroxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-85-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-ethoxyphenyl)amino]-8-ethyl- (9CI) (CA INDEX NAME)



RN 185039-86-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(3,4-dimethoxyphenyl)amino]-8-ethyl- (9CI) (CA INDEX NAME)



RN 185039-87-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-[(3,4,5-trimethoxyphenyl)amino]- (9CI) (CA INDEX NAME)



RN 185039-88-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(3-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 185039-89-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-90-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[5-(4-methyl-1-piperazinyl)pentyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-91-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-92-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(3,5-dimethoxyphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-93-4 CAPLUS
CN Benzeneacetic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 185039-94-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(6-methoxy-3-pyridinyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-95-6 CAPLUS
CN Benzeneacetic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 185039-96-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(3-hydroxyphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 185039-97-8 CAPLUS
CN Benzoic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 185039-98-9 CAPLUS
CN Benzoic acid, 3-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 185039-99-0 CAPLUS
CN Benzoic acid, 3-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 185040-00-0 CAPLUS
CN Benzenebutanoic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 185040-01-1 CAPLUS
CN Benzenebutanoic acid, 4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 185040-02-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-ethyl-2-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 185040-07-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-bromo-6-chlorophenyl)-8-ethyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



RN 185040-17-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-ethyl-6-phenyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



=> s l6 not l7 not l9 not l11 not l13
L15 61 L6 NOT L7 NOT L9 NOT L11 NOT L13

=> sort py l15
SORT ENTIRE ANSWER SET? (Y)/N:.
PROCESSING COMPLETED FOR L15
L16 61 SORT L15 PY

=> d 1-45 cbib pi fhitstr

L16 ANSWER 1 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
1998:26635 Document No. 128:149553 In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. Panek, Robert L.; Lu, Gina H.; Klutchko, Sylvester R.; Batley, Brian L.; Dahring, Tawny K.; Hamby, James M.; Hallak, Hussein; Doherty, Annette M.; Keiser, Joan A. (Departments of Vascular and Cardiac Diseases, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI, USA). Journal of Pharmacology and Experimental Therapeutics, 283(3), 1433-1444 (English) 1997. CODEN: JPETAB. ISSN: 0022-3565. Publisher: Williams & Wilkins.
IT **212391-63-4**, PD 166285
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. characterization of protein tyrosine kinase inhibitor PD 166285)
RN 212391-63-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L16 ANSWER 2 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
1997:463854 Document No. 127:140340 Prolonged vascular effects with drug loaded nanoparticles. Panek, R.; Chen, W.; Labhasetwar, V.; Hamby, J.; Levy, R.; Uprichard, A.; Keiser, J. (Parke-Davis Pharmaceutical Research, Ann Arbor, MI, 48105, USA). Proceedings of the International Symposium on Controlled Release of Bioactive Materials, 24th, 819-820 (English) 1997. CODEN: PCRMEY. ISSN: 1022-0178. Publisher: Controlled Release Society, Inc..
IT **212391-63-4**, PD 166285
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(prolonged vascular effects with drug loaded nanoparticles)
RN 212391-63-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L16 ANSWER 3 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
1998:600713 Document No. 129:316187 Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8H-pyrido[2,3-d]pyrimidines:

Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors. Boschelli, Diane H.; Wu, Zhipei; Klutchko, Sylvester R.; Showalter, H. D. Hollis; Hamby, James M.; Lu, Gina H.; Major, Terry C.; Dahring, Tawny K.; Batley, Brian; Panek, Robert L.; Keiser, Joan; Hartl, Brian G.; Kraker, Alan J.; Klohs, Wayne D.; Roberts, Bill J.; Patmore, Sandra; Elliott, William L.; Steinkampf, Randy; Bradford, Laura A.; Hallak, Hussein; Doherty, Annette M. (Department of Medicinal Chemistry, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company, Ann Arbor, MI, 48105, USA). Journal of Medicinal Chemistry, 41(22), 4365-4377 (English) 1998. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.

IT **214983-06-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation and tyrosine kinase inhibitory activity of aminopyrido[2,3-d]pyrimidines)

RN 214983-06-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-methyl-6-phenyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



L16 ANSWER 4 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

1998:496546 Document No. 129:211390 2-Substituted Aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity. Klutchko, Sylvester R.; Hamby, James M.; Boschelli, Diane H.; Wu, Zhipei; Kraker, Alan J.; Amar, Aneesa M.; Hartl, Brian G.; Shen, Cynthia; Klohs, Wayne D.; Steinkampf, Randall W.; Driscoll, Denise L.; Nelson, James M.; Elliott, William L.; Roberts, Billy J.; Stoner, Chad L.; Vincent, Patrick W.; Dykes, Donald J.; Panek, Robert L.; Lu, Gina H.; Major, Terry C.; Dahring, Tawny K.; Hallak, Hussein; Bradford, Laura A.; Showalter, H. D. Hollis; Doherty, Annette M. (Departments of Chemistry Cancer Research Vascular and Cardiac Diseases and Pharmacokinetics and Drug Metabolism Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI, 48105, USA). Journal of Medicinal Chemistry, 41(17), 3276-3292 (English) 1998. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.

IT **212391-58-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MFM (Metabolic formation); SPN (Synthetic preparation); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation)
(preparation of aminopyridopyrimidinones as tyrosine kinase inhibitors and anticancer agents)

RN 212391-58-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-[[4-(2-aminoethoxy)phenyl]amino]-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 5 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
1998:269543 Document No. 128:316912 Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido[2,3-d]pyrimidine Inhibitors. Trumpp-Kallmeyer, Susanne; Rubin, J. Ronald; Humblet, Christine; Hamby, James M.; Showalter, H. D. Hollis (Division of Warner-Lambert Company, Parke-Davis Pharmaceutical Research, Ann Arbor, MI, 48105, USA). Journal of Medicinal Chemistry, 41(11), 1752-1763 (English) 1998. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.
IT **185039-31-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(development of binding model to protein tyrosine kinases for substituted pyrido[2,3-d]pyrimidine inhibitors)
RN 185039-31-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(diethylamino)propyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 6 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2000:47493 Document No. 132:175450 Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy. Dimitroff, Charles J.; Klohs, Wayne; Sharma, Amarnath; Pera, Paula; Driscoll, Denise; Veith, Jean; Steinkampf, Randall; Schroeder, Mel; Klutchko, Sylvester; Sumlin, Adam; Henderson, Barbara; Dougherty, Thomas J.; Bernacki, Ralph J. (Harvard Skin Disease Research Center, Harvard Medical School, Boston, MA, USA). Investigational New Drugs, 17(2), 121-135 (English) 1999. CODEN: INNDDK. ISSN: 0167-6997. Publisher: Kluwer Academic Publishers.
IT **212391-63-4**, PD 166285
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(anti-angiogenic activity of selected receptor tyrosine kinase inhibitors)
RN 212391-63-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L16 ANSWER 7 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2000:41826 Document No. 132:202742 Inhibition of src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Moasser, Mark M.; Srethapakdi, Mary; Sachar, Komal S.; Kraker, Alan J.; Rosen, Neal (Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA). Cancer Research, 59(24), 6145-6152 (English) 1999. CODEN: CNREA8. ISSN: 0008-5472. Publisher: AACR Subscription Office.
IT **260415-63-2**, PD 173955
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(inhibition of src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest)
RN 260415-63-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 8 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

1999:414829 Document No. 131:67714 Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Roginskaya, V.; Zuo, S.; Caudell, E.; Nambudiri, G.; Kraker, A. J.; Corey, S. J. (Department of Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh, PA, 15213, USA). Leukemia, 13(6), 855-861 (English) 1999. CODEN: LEUKED. ISSN: 0887-6924. Publisher: Stockton Press.

IT **212391-63-4**, PD 166285
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth)

RN 212391-63-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L16 ANSWER 9 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2000:621985 Document No. 133:344305 Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Kraker, A. J.; Hartl, B. G.; Amar, A. M.; Barvian, M. R.; Showalter, H. D. H.; Moore, C. W. (Department of Cancer Research, Parke-Davis Pharmaceutical Research, Division of the Warner-Lambert Co., Ann Arbor, MI, 48105, USA). Biochemical Pharmacology, 60(7), 885-898 (English) 2000. CODEN: BCPCA6. ISSN: 0006-2952. Publisher: Elsevier Science Inc..

IT **185039-91-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(biochem. and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors)

RN 185039-91-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 10 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2000:438768 Document No. 133:144554 The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Dorsey, Jay F.; Jove, Richard; Kraker, Alan J.; Wu, Jie (Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute and the Departments of Medical Microbiology and Immunology, University of South Florida College of Medicine, Tampa, FL, 33612, USA). Cancer Research, 60(12), 3127-3131 (English) 2000. CODEN: CNREA8. ISSN: 0008-5472. Publisher: American Association for Cancer Research.
IT **287204-45-9**, PD 180970
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells)
RN 287204-45-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-fluoro-3-methylphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 11 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2001:880225 Document No. 136:147205 Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator. Wang, Yuli; Li, Jun; Booher, Robert N.; Kraker, Alan; Lawrence, Theodore; Leopold, Wilbur R.; Sun, Yi (Departments of Cancer Molecular Sciences, Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, MI, 48105, USA). Cancer Research, 61(22), 8211-8217 (English) 2001. CODEN: CNREA8. ISSN: 0008-5472. Publisher: American Association for Cancer Research.
IT **212391-63-4**, PD 166285
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(radiosensitization of p53 mutant cells by G2 checkpoint abrogator)

RN 212391-63-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L16 ANSWER 12 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2001:472531 Document No. 135:81944 Angiogenesis and vascular permeability modulators and inhibitors. Cheresh, David A.; Eliceiri, Brian; Paul, Robert (Scripps Research Institute, USA). PCT Int. Appl. WO 2001045751 A1 20010628, 132 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2000-US35396 20001222. PRIORITY: US 1999-470881 19991222; US 2000-538248 20000329.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001045751	A1	20010628	WO 2000-US35396	20001222
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6685938	B1	20040203	US 1999-470881	19991222
	CA 2395136	AA	20010628	CA 2000-2395136	20001222
	EP 1250155	A1	20021023	EP 2000-990365	20001222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2000016547	A	20021029	BR 2000-16547	20001222
	JP 2003518077	T2	20030603	JP 2001-546690	20001222
	AU 781444	B2	20050526	AU 2001-27400	20001222
	NO 2002003036	A	20020722	NO 2002-3036	20020621

IT **260415-63-2**, PD 173955
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(angiogenesis and vascular permeability modulators and inhibitors)
RN 260415-63-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 13 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2003:10878 Document No. 138:395641 Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). La Rosee, Paul; Corbin, Amie S.; Stoffregen, Eric P.; Deininger, Michael W.; Druker, Brian J. (Division of Hematology and Medical Oncology, Oregon Health and Sciences University Cancer Institute, Portland, OR, 97239, USA). Cancer Research, 62(24), 7149-7153 (English) 2002. CODEN: CNREA8. ISSN: 0008-5472. Publisher: American Association for Cancer Research.
IT **287204-45-9**, PD180970
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(activity of Bcr-Abl kinase inhibitor PD180970 against Abl kinase domain mutations that cause resistance to imatinib mesylate)
RN 287204-45-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-fluoro-3-methylphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 14 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2002:950285 Document No. 139:17213 Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Huang, Mei; Dorsey, Jay F.; Epling-Burnette, P. K.; Nimmanapalli, Ramadevi; Landowski, Terry H.; Mora, Linda B.; Niu, Guilian; Sinibaldi,

Dominic; Bai, Fanqi; Kraker, Alan; Yu, Hua; Moscinski, Lynn; Wei, Sheng; Djeu, Julie; Dalton, William S.; Bhalla, Kapil; Loughran, Thomas P.; Wu, Jie; Jove, Richard (Molecular Oncology, H Lee Moffitt Cancer Center, Research Institute, Tampa, FL, 33612, USA). Oncogene, 21(57), 8804-8816 (English) 2002. CODEN: ONCNES. ISSN: 0950-9232. Publisher: Nature Publishing Group.

IT **287204-45-9**, PD180970
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells)

RN 287204-45-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-fluoro-3-methylphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 15 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2002:818743 Document No. 138:331328 Molecular characterization and sensitivity of STI-571 (imatinib mesylate, gleevec)-resistant, bcr-abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Nimmanapalli, Ramadevi; O'Bryan, Erica; Huang, Mei; Bali, Purva; Burnette, Pearlie Kay; Loughran, Thomas; Tepperberg, James; Jove, Richard; Bhalla, Kapil (Interdisciplinary Oncology Program, Moffitt Cancer Center, University of South Florida, Tampa, FL, 33612, USA). Cancer Research, 62(20), 5761-5769 (English) 2002. CODEN: CNREA8. ISSN: 0008-5472. Publisher: American Association for Cancer Research.

IT **287204-45-9**, PD180970
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mol. characterization and sensitivity of STI-571 (imatinib mesylate, gleevec)-resistant, bcr-abl-pos., human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin)

RN 287204-45-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-fluoro-3-methylphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 16 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2002:649655 Document No. 138:32963 Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Dorsey, J. F.; Cunnick, J. M.; Lanehart, R.; Huang, M.; Kraker, A. J.; Bhalla, K. N.; Jove, R.; Wu, J. (Molecular Oncology and Experimental Therapeutics Program, H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL, USA). Leukemia, 16(9), 1589-1595 (English) 2002. CODEN: LEUKED. ISSN: 0887-6924. Publisher: Nature Publishing Group.
IT **185039-63-8**, PD 164199
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors)
RN 185039-63-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



L16 ANSWER 17 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2002:593669 Document No. 138:198235 Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Wisniewski, David; Lambek, Caryl L.; Liu, Chongyuan; Strife, Annabel; Veach, Darren R.; Nagar, Bhushan; Young, Matthew A.; Schindler, Thomas; Bornmann, William G.; Bertino, Joseph R.; Kuriyan, John; Clarkson, Bayard (Molecular Pharmacology and Chemistry Program, New York, NY, 10021, USA). Cancer Research, 62(15), 4244-4255 (English) 2002. CODEN: CNREA8. ISSN: 0008-5472. Publisher: American Association for Cancer Research.
IT **185039-91-2**, PD 166326
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(characterization of potent inhibitors of Bcr-Abl and the c-kit

receptor tyrosine kinases and their antitumor effect)
RN 185039-91-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 18 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2002:593668 Document No. 137:274989 Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Nagar, Bhushan; Bornmann, William G.; Pellicena, Patricia; Schindler, Thomas; Veach, Darren R.; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John (Departments of Molecular and Cell Biology and Chemistry and Howard Hughes Medical Institute, University of California, Berkeley, CA, 94720, USA). Cancer Research, 62(15), 4236-4243 (English) 2002. CODEN: CNREA8. ISSN: 0008-5472. Publisher: American Association for Cancer Research.
IT **260415-63-2D**, PD 173955, complex with c-Abl protein kinase
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(crystal structures of kinase domain of c-Abl in complex with small mol. inhibitors PD173955 and imatinib (STI-571))
RN 260415-63-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 19 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2002:331865 Document No. 136:365750 Diagnostic and drug screening use of cellular kinases involved in human cytomegalovirus infection and treatment of HCMV infection using kinase inhibitors. Schubart, Daniel; Habenberger, Peter; Stein-Gerlach, Matthias; Bevec, Dorian (Axxima Pharmaceuticals Aktiengesellschaft, Germany). Eur. Pat. Appl. EP 1201765 A2 20020502, 49 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI,

LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR. (English). CODEN: EPXXDW. APPLICATION: EP 2001-124604 20011015. PRIORITY: US 2000-PV240750 20001016.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1201765	A2	20020502	EP 2001-124604	20011015
	EP 1201765	A3	20030827		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003082519	A1	20030501	US 2001-981397	20011016
	US 6849409	B2	20050201		

IT **185039-47-8**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diagnostic and drug screening use of cellular kinases involved in human cytomegalovirus infection and treatment of HCMV infection using kinase inhibitors)
RN 185039-47-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 20 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2002:201122 Document No. 136:365859 Wild-type TP53 inhibits G2-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor. Li, Jun; Wang, Yuli; Sun, Yi; Lawrence, Theodore S. (Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, 48109, USA). Radiation Research, 157(3), 322-330 (English) 2002. CODEN: RAREAE. ISSN: 0033-7587. Publisher: Radiation Research Society.

IT **212391-63-4**, PD0166285
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(wild-type TP53 inhibits G2-phase checkpoint abrogation and radiosensitization induced by WEE1 kinase inhibitor PD0166285)
RN 212391-63-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L16 ANSWER 21 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2002:171896 Document No. 136:232316 7-Oxopyridopyrimidines as inhibitors of cellular proliferation, and particularly as inhibitors of p38 kinase, for treatment of p38-related conditions. Chen, Jian Jeffrey; Dunn, James Patrick; Goldstein, David Michael; Lim, Julie Anne (F. Hoffmann-La Roche Ag, Switz.). PCT Int. Appl. WO 2002018380 A1 20020307, 135 pp.
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-EP9689 20010822. PRIORITY: US 2000-PV229584 20000831.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018380	A1	20020307	WO 2001-EP9689	20010822
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2420286	AA	20020307	CA 2001-2420286	20010822
	AU 2001093784	A5	20020313	AU 2001-93784	20010822
	EP 1315726	A1	20030604	EP 2001-974206	20010822
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001013628	A	20030701	BR 2001-13628	20010822
	JP 2004507541	T2	20040311	JP 2002-523895	20010822
	US 2002055513	A1	20020509	US 2001-943338	20010830
	US 6518276	B2	20030211		
	US 2002137756	A1	20020926	US 2001-943407	20010830
	US 6506749	B2	20030114		
	US 2003153586	A1	20030814	US 2002-230723	20020829
	US 6861423	B2	20050301		

	US 2003144307	A1	20030731	US 2002-315633	20021210
	US 6753427	B2	20040622		
	ZA 2003001079	A	20040507	ZA 2003-1079	20030207
	US 2004192709	A1	20040930	US 2004-816554	20040401

IT **402928-12-5P**
RL: BYP (Byproduct); PREP (Preparation)
(byproduct; preparation of oxopyridopyrimidines as p38 kinase inhibitors)
RN 402928-12-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[(trans-4-methoxycyclohexyl)amino]-8-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L16 ANSWER 22 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2002:171895 Document No. 136:216763 Preparation of 7-oxopyridopyrimidines as p38 MAP kinase inhibitors. Arzeno, Humberto Bartolome; Chen, Jian Jeffrey; Dunn, James Patrick; Goldstein, David Michael; Lim, Julie Anne (F. Hoffmann-La Roche Ag, Switz.). PCT Int. Appl. WO 2002018379 A2 20020307, 64 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-EP9688 20010822. PRIORITY: US 2000-PV229577 20000831.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018379	A2	20020307	WO 2001-EP9688	20010822
	WO 2002018379	A3	20020725		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2420122	AA	20020307	CA 2001-2420122	20010822
	AU 2002012147	A5	20020313	AU 2002-12147	20010822
	EP 1315727	A2	20030604	EP 2001-980258	20010822
	EP 1315727	B1	20050629		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001013590	A	20030722	BR 2001-13590	20010822
JP 2004507540	T2	20040311	JP 2002-523894	20010822
AT 298751	E	20050715	AT 2001-980258	20010822
US 2002055513	A1	20020509	US 2001-943338	20010830
US 6518276	B2	20030211		
US 2003153586	A1	20030814	US 2002-230723	20020829
US 6861423	B2	20050301		
US 2003144307	A1	20030731	US 2002-315633	20021210
US 6753427	B2	20040622		
ZA 2003001078	A	20040507	ZA 2003-1078	20030207
US 2004192709	A1	20040930	US 2004-816554	20040401

IT **402740-31-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 7-oxopyridopyrimidines as p38 MAP kinase inhibitors)

RN 402740-31-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-8-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 23 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2002:86818 Document No. 136:395481 Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Bishop, Philippe C.; Myers, Timothy; Robey, Robert; Fry, David W.; Liu, Edison T.; Blagosklonny, Mikhail V.; Bates, Susan E. (Medicine Branch, NCI, NIH, Bethesda, MD, 20892, USA). Oncogene, 21(1), 119-127 (English) 2002. CODEN: ONCNES. ISSN: 0950-9232. Publisher: Nature Publishing Group.

IT **212391-63-4**, NSC 691869
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sensitivity of cancer cells to inhibitors of EGF receptor family)

RN 212391-63-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L16 ANSWER 24 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2002:10204 Document No. 136:64111 New strategy for leukemia therapy. Wang, Jean Y. J.; Vigneri, Paolo (The Regents of the University of California, USA). PCT Int. Appl. WO 2002000024 A1 20020103, 63 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-US20602 20010629. PRIORITY: US 2000-2000/PV215595 20000630.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002000024	A1	20020103	WO 2001-US20602	20010629
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2003162740	A1	20030828	US 2002-312918	20021227

IT **260415-63-2**, PD 173955
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PD 173955; apoptotic leukemia therapy by translocation of Bcr-Abl to the cell nucleus)
RN 260415-63-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 25 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2003:809105 Document No. 140:122306 Inhibition of Wild-Type and Mutant Bcr-Abl by Pyrido-Pyrimidine-Type Small Molecule Kinase Inhibitors. von Bubnoff, Nikolas; Veach, Darren R.; Miller, W. Todd; Li, Wanqing; Saenger, Jana; Peschel, Christian; Bornmann, William G.; Clarkson, Bayard; Duyster, Justus (Department of Internal Medicine III, Technical University of Munich, Munich, Germany). Cancer Research, 63(19), 6395-6404 (English) 2003. CODEN: CNREA8. ISSN: 0008-5472. Publisher: American Association for Cancer Research.
IT **185039-91-2**, PD166326
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small mol. kinase inhibitors in relation to leukemia treatment)
RN 185039-91-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 26 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2003:738968 Document No. 139:358017 Kinases, Homology Models, and High Throughput Docking. Diller, David J.; Li, Rixin (Pharmacopeia, Inc., Princeton, NJ, 08543-5350, USA). Journal of Medicinal Chemistry, 46(22), 4638-4647 (English) 2003. CODEN: JMCMAR. ISSN: 0022-2623. Publisher: American Chemical Society.
IT **185039-63-8D**, derivs.
RL: PAC (Pharmacological activity); PRP (Properties); BIOL (Biological study)
(protein kinases and homol. models and high throughput docking in relation to drug discovery and design)
RN 185039-63-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-

(phenylamino)- (9CI) (CA INDEX NAME)



L16 ANSWER 27 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2003:665548 Document No. 139:316606 Bone-Targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agents. Vu, Chi B.; Luke, George P.; Kawahata, Noriyuki; Shakespeare, William C.; Wang, Yihan; Sundaramoorthi, Raji; Metcalf, Chester A.; Keenan, Terence P.; Pradeepan, Selvi; Corpuz, Evelyn; Merry, Taylor; Bohacek, Regine S.; Dalgarno, David C.; Narula, Surinder S.; Van Schravendijk, Marie Rose; Ram, Mary K.; Adams, Susan; Liou, Shuenn; Keats, Jeffrey A.; Violette, Shelia M.; Guan, Wei; Weigele, Manfred; Sawyer, Tomi K. (ARIAD Pharmaceuticals, Inc., Cambridge, MA, 02139-4234, USA). Bioorganic & Medicinal Chemistry Letters, 13(18), 3071-3074 (English) 2003. CODEN: BMCLE8. ISSN: 0960-894X. OTHER SOURCES: CASREACT 139:316606. Publisher: Elsevier Science B.V..
IT **185039-63-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(bone-targeted pyridopyrimidinones as inhibitors of Src tyrosine kinase and antiresorptive agents)
RN 185039-63-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)- (9CI) (CA INDEX NAME)



L16 ANSWER 28 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2003:532334 Document No. 139:95468 Method of treatment of myocardial infarction using Src kinase inhibitors. Cheresh, David A.; Paul, Robert; Eliceiri, Brian (USA). U.S. Pat. Appl. Publ. US 2003130209 A1 20030710, 37 pp., Cont.-in-part of U.S. Ser. No. 538,248. (English). CODEN: USXXCO. APPLICATION: US 2002-298377 20021118. PRIORITY: US 1999-470881 19991222; US 2000-538248 20000329.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003130209	A1	20030710	US 2002-298377	20021118
	US 6685938	B1	20040203	US 1999-470881	19991222
	CA 2506476	AA	20040603	CA 2003-2506476	20031118
	WO 2004045563	A2	20040603	WO 2003-US37653	20031118
	WO 2004045563	A3	20041223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1567160	A2	20050831	EP 2003-790028	20031118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 2004214836	A1	20041028	US 2004-801050	20040315

IT **260415-63-2**, PD173955
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PD173955, Src kinase inhibitor; method of treatment of myocardial infarction using Src kinase inhibitors)
RN 260415-63-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 29 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2003:409452 Document No. 139:226295 Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Tanis, Keith Q.; Veach, Darren; Duewel, Henry S.; Bornmann, William G.; Koleske, Anthony J. (Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT, 06520, USA). Molecular and Cellular Biology, 23(11), 3884-3896 (English) 2003. CODEN: MCEBD4. ISSN: 0270-7306. Publisher: American Society for Microbiology.
IT **287204-45-9**, PD180970
RL: BSU (Biological study, unclassified); NUU (Other use, unclassified); BIOL (Biological study); USES (Uses)
(inhibitor; drug sensitivities of Abl and Arg kinases)
RN 287204-45-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-fluoro-3-methylphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 30 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2003:281040 Document No. 139:81284 Structural basis for the autoinhibition of c-Abl tyrosine kinase. Nagar, Bhushan; Hantschel, Oliver; Young, Matthew A.; Scheffzek, Klaus; Veach, Darren; Bornmann, William; Clarkson, Bayard; Superti-Furga, Giulio; Kuriyan, John (Howard Hughes Medical Institute, University of California, Berkeley, CA, 94720, USA). Cell (Cambridge, MA, United States), 112(6), 859-871 (English) 2003. CODEN: CELLB5. ISSN: 0092-8674. Publisher: Cell Press.
IT **185039-91-2D**, PD166326, complex with c-Abl tyrosine kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(structure of truncated forms of c-Abl tyrosine kinase in complexes with small mol. inhibitors)
RN 185039-91-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 31 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2003:273844 Document No. 139:345426 A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against STI571-resistant Bcr-abl Mutants. Huron, David R.; Gorre, Mercedes E.; Kraker, Alan J.; Sawyers, Charles L.; Rosen, Neal; Moasser, Mark M. (Memorial Sloan-Kettering Cancer Center and Program in Pharmacology, Weill Graduate School of Medical Sciences, Cornell University, New York, NY, 10021, USA). Clinical Cancer Research, 9(4), 1267-1273 (English) 2003. CODEN: CCREF4. ISSN: 1078-0432. Publisher: American Association for Cancer Research.
IT **185039-91-2**, PD166326
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel pyridopyrimidine inhibitor (PD166326) of Bcr-abl tyrosine kinase

is effective against STI571-resistant Bcr-abl mutants in chronic myelogenous leukemia)

RN 185039-91-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 32 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2003:273838 Document No. 139:345024 Is Another Bcr-Abl Inhibitor Needed for Chronic Myelogenous Leukemia?. Sausville, Edward A. (Developmental Therapeutics Program, National Cancer Institute, Rockville, MD, 20852, USA). Clinical Cancer Research, 9(4), 1233-1234 (English) 2003. CODEN: CCREF4. ISSN: 1078-0432. Publisher: American Association for Cancer Research.

IT **185039-91-2**, PD166326

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antitumor activity of Bcr-Abl inhibitor PD166326 in chronic myelogenous leukemia)

RN 185039-91-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 33 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2003:5788 Document No. 138:56078 Preparation of phosphorus-substituted pyridopyrimidones as therapeutic agents. Metcalf, Chester A., III; Shakespeare, William C.; Sawyer, Tomi K.; Wang, Yihan; Bohacek, Regine (Ariad Pharmaceuticals, Inc., USA). PCT Int. Appl. WO 2003000270 A1 20030103, 164 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,

UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US19605 20020621. PRIORITY: US 2001-2001/PV299920 20010621.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003000270	A1	20030103	WO 2002-US19605	20020621
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003100572	A1	20030529	US 2002-177520	20020621
	EP 1408985	A1	20040421	EP 2002-739940	20020621
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

IT **344891-17-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phosphorus-substituted pyridopyrimidones as therapeutic agents)

RN 344891-17-4 CAPLUS

CN Phosphonic acid, [[4-[[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]phenyl]methylene]bis- (9CI) (CA INDEX NAME)



L16 ANSWER 34 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2005:60456 Document No. 142:403584 S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. Mizenina, Olga A.; Moasser, Mark M. (Memorial Sloan-Kettering Cancer Center, Sloan-Kettering Institute, New York, NY, USA). Cell Cycle, 3(6), 796-803 (English) 2004. CODEN: CCEYAS. ISSN: 1538-4101. Publisher: Landes Bioscience.

IT **185039-91-2**, PD166326
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(S-phase inhibition of cell cycle progression by a class of pyridopyrimidine tyrosine kinase inhibitors)

RN 185039-91-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 35 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2005:19286 Document No. 142:254023 Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors. Wissing, Josef; Godl, Klaus; Brehmer, Dirk; Blencke, Stephanie; Weber, Martina; Habenberger, Peter; Stein-Gerlach, Matthias; Missio, Andrea; Cotten, Matt; Mueller, Stefan; Daub, Henrik (Axxima Pharmaceuticals AG, Munich, 81377, Germany). Molecular and Cellular Proteomics, 3(12), 1181-1193 (English) 2004. CODEN: MCPOBS. ISSN: 1535-9476. Publisher: American Society for Biochemistry and Molecular Biology.

IT **212391-58-7**, PP58

RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)

(chemical proteomic anal. reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors)

RN 212391-58-7 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-[[4-(2-aminoethoxy)phenyl]amino]-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 36 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2004:1156620 Document No. 142:71185 Phage display assay for detecting protein binding by screening libraries of compounds against phage-displayed polypeptides. Lockhart, David J.; Zarrinkar, Patrick Parvis; Treiver, Daniel Kelly (Ambit Biosciences, Inc., USA; Ambit Biosciences Corporation). PCT Int. Appl. WO 2004113556 A2 20041229, 37 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,

FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2004-US19943 20040621. PRIORITY: US 2003-PV480587 20030620.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004113556	A2	20041229	WO 2004-US19943	20040621
	WO 2004113556	C1	20050310		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005009099	A1	20050113	US 2004-873835	20040621

IT **260415-63-2**, PD-173955
RL: NUU (Other use, unclassified); USES (Uses)
(reference kinase modulator; phage display assay for detecting protein binding by screening libraries of compds. against phage-displayed polypeptides)

RN 260415-63-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 37 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2004:1056732 Document No. 142:106797 Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Corbin, Amie S.; Griswold, Ian J.; La Rosee, Paul; Yee, Kevin W. H.; Heinrich, Michael C.; Reimer, Corinne L.; Druker, Brian J.; Deininger, Michael W. N. (Oregon Health and Science University Cancer Institute, Portland, USA). Blood, 104(12), 3754-3757 (English) 2004. CODEN: BLOOAW. ISSN: 0006-4971. Publisher: American Society of Hematology.

IT **287204-45-9**, PD180970
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(sensitivity of oncogenic KIT mutant cells to the kinase inhibitors MLN518 and PD180970)

RN 287204-45-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-fluoro-3-methylphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 38 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2004:954402 Document No. 142:147823 Efficient optimization strategy for marginal hits active against abl tyrosine kinases. Tkachenko, Sergey E.; Okun, Ilya; Balakin, Konstantin V.; Petersen, Charles E.; Ivanenkov, Yan A.; Savchuk, Nikolay P.; Ivashchenko, Andrey A. (Chemical Diversity Labs, Inc., San Diego, CA, 92121, USA). Current Drug Discovery Technologies, 1(3), 201-210 (English) 2004. CODEN: CDDTAF. ISSN: 1570-1638. Publisher: Bentham Science Publishers Ltd..

IT **287204-45-9**, PD 180790

RL: BSU (Biological study, unclassified); BIOL (Biological study) (efficient optimization strategy for marginal hits active against abl tyrosine kinases)

RN 287204-45-9 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-fluoro-3-methylphenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 39 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2004:919837 Document No. 142:168689 Dual inhibitors of Src and Abl tyrosine kinases. Boschelli, Diane H. (Chem. Screening Sci., Wyeth Res., Pearl River, NY, 10965, USA). Drug Design Reviews--Online, 1(3), 203-214 (English) 2004. CODEN: DDRRAM. URL: http://saturn.bids.ac.uk/cgi-bin/ds_deliver/1/u/d/ISIS/13405279.1/ben/ddro/2004/00000001/00000003/art00003/E Publisher: Bentham Science Publishers Ltd..

IT **260415-63-2**, PD 173955

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dual Src/Abl inhibitor PD 173955 may prove to be highly effective agents for treatment of CML as first line and for patients who develop gleevec resistance as SFKs are implicated in Bcr-Abl signaling)

RN 260415-63-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 40 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2004:905617 Document No. 141:374724 Method using a Src family tyrosine kinase inhibitor for the treatment of myocardial infarction. Cheresh, David A.; Paul, Robert; Eliceiri, Brian (USA). U.S. Pat. Appl. Publ. US 2004214836 A1 20041028, 44 pp., Cont.-in-part of Appl. No. PCT/US03/37653. (English). CODEN: USXXCO. APPLICATION: US 2004-801050 20040315. PRIORITY: US 1998-PV87220 19980529; WO 1999-US11780 19990528; US 1999-470881 19991222; US 2000-538248 20000329; US 2002-298377 20021118; WO 2003-US37653 20031118.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004214836	A1	20041028	US 2004-801050	20040315
	WO 9961590	A1	19991202	WO 1999-US11780	19990528
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6685938	B1	20040203	US 1999-470881	19991222
	US 2003130209	A1	20030710	US 2002-298377	20021118
	WO 2004045563	A2	20040603	WO 2003-US37653	20031118
	WO 2004045563	A3	20041223		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,				

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
WO 2005089366 A2 20050929 WO 2005-US8719 20050315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

IT **260415-63-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Src family tyrosine kinase inhibitor for treatment of myocardial infarction)

RN 260415-63-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 41 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2004:762799 Document No. 141:374350 SRCircumventing imatinib resistance. Deininger, Michael W. N.; Druker, Brian J. (Center for Hematologic Malignancies L592, Oregon Health and Science University Cancer Institute, Portland, OR, 97239, USA). Cancer Cell, 6(2), 108-110 (English) 2004. CODEN: CCAECI. ISSN: 1535-6108. Publisher: Cell Press.

IT **260415-63-2**, PD 173955
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(SRCircumventing imatinib resistance)

RN 260415-63-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]- (9CI) (CA INDEX NAME)



L16 ANSWER 42 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2004:607111 Document No. 141:274709 Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation. Deng, Xinzhu; Hofmann, E. Randal; Villanueva, Alberto; Hobert, Oliver; Capodieci, Paola; Veach, Darren R.; Yin, Xianglei; Campodonico, Luis; Glekas, Athanasios; Cordon-Cardo, Carlos; Clarkson, Bayard; Bornmann, William G.; Fuks, Zvi; Hengartner, Michael O.; Kolesnick, Richard (Laboratory of Signal Transduction, Memorial Sloan-Kettering Cancer Center, New York, NY, 10021, USA). Nature Genetics, 36(8), 906-912 (English) 2004. CODEN: NGENEC. ISSN: 1061-4036. Publisher: Nature Publishing Group.
IT **185039-91-2**, PD166326
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nematode ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation)
RN 185039-91-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 43 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2004:583213 Document No. 142:147947 Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. Tipping, A. J.; Baluch, S.; Barnes, D. J.; Veach, D. R.; Clarkson, B. M.; Bornmann, W. G.; Mahon, F. X.; Goldman, J. M.; Melo, J. V. (Department of Haematology, Imperial College London, Hammersmith Hospital, London, UK). Leukemia, 18(8), 1352-1356 (English) 2004. CODEN: LEUKED. ISSN: 0887-6924. Publisher: Nature Publishing Group.
IT **185039-91-2**, PD166326
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PD166326 significantly inhibited proliferation of Ba/F3, Baf-BCR-ABL-s, Baf-BCR-ABL-r and human AR230-s, AR230-r cell lines

suggesting its potent cytotoxic effect against imatinib resistant and sensitive chronic myeloid leukemia cells)

RN 185039-91-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[3-(hydroxymethyl)phenyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 44 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2004:533970 Document No. 141:65088 Methods and compositions for the prevention or treatment of neoplasia comprising a COX-2 inhibitor in combination with an epidermal growth factor receptor antagonist. Masferrer, Jaime (Pharmacia Corporation, USA). U.S. Pat. Appl. Publ. US 2004127470 A1 20040701, 103 pp., Cont.-in-part of U.S. Ser. No. 470,951. (English). CODEN: USXXCO. APPLICATION: US 2003-651916 20030829. PRIORITY: US 1998-PV113786 19981223; US 1999-470951 19991222.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004127470	A1	20040701	US 2003-651916	20030829
EP 1522313	A1	20050413	EP 2004-26577	19991222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO, CY				
WO 2005037259	A2	20050428	WO 2004-US27574	20040825
WO 2005037259	A3	20050804		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

IT **305820-76-2**, PD-173956

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as EGFR antagonist; COX-2 inhibitor in combination with epidermal growth factor receptor antagonist for prevention or treatment of neoplasia)

RN 305820-76-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl- (9CI) (CA INDEX NAME)



L16 ANSWER 45 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2004:419904 Document No. 142:70669 Characterization of a Conserved Structural Determinant Controlling Protein Kinase Sensitivity to Selective Inhibitors. Blencke, Stephanie; Zech, Birgit; Engkvist, Ola; Greff, Zoltan; Orfi, Laszlo; Horvath, Zoltan; Keri, Gyoergy; Ullrich, Axel; Daub, Henrik (Axxima Pharmaceuticals AG, Munchen, 81377, Germany). Chemistry & Biology, 11(5), 691-701 (English) 2004. CODEN: CBOLE2. ISSN: 1074-5521. Publisher: Cell Press.
IT **212391-58-7**, PP 58
RL: BSU (Biological study, unclassified); BIOL (Biological study) (characterization of a conserved structural determinant controlling protein kinase inhibitor sensitivity)
RN 212391-58-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-[[4-(2-aminoethoxy)phenyl]amino]-6-(2,6-dichlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



=>
=> d 1 19 21 22 cbib pi hitstr

L16 ANSWER 1 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
1998:26635 Document No. 128:149553 In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. Panek, Robert L.; Lu, Gina H.; Klutchko, Sylvester R.; Batley, Brian L.; Dahring, Tawny K.; Hamby, James M.; Hallak, Hussein; Doherty, Annette M.; Keiser, Joan A. (Departments of Vascular and Cardiac Diseases, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI, USA). Journal of Pharmacology and Experimental Therapeutics, 283(3), 1433-1444 (English) 1997. CODEN: JPETAB. ISSN: 0022-3565. Publisher: Williams & Wilkins.
IT **212391-63-4**, PD 166285
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or

effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. characterization of protein tyrosine kinase inhibitor PD 166285)

RN 212391-63-4 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-8-methyl-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

L16 ANSWER 19 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN

2002:331865 Document No. 136:365750 Diagnostic and drug screening use of cellular kinases involved in human cytomegalovirus infection and treatment of HCMV infection using kinase inhibitors. Schubart, Daniel; Häbenberger, Peter; Stein-Gerlach, Matthias; Bevec, Dorian (Axxima Pharmaceuticals Aktiengesellschaft, Germany). Eur. Pat. Appl. EP 1201765 A2 20020502, 49 pp. DESIGNATED STATES: R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR. (English). CODEN: EPXXDW. APPLICATION: EP 2001-124604 20011015. PRIORITY: US 2000-PV240750 20001016.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1201765	A2	20020502	EP 2001-124604	20011015
EP 1201765	A3	20030827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003082519	A1	20030501	US 2001-981397	20011016
US 6849409	B2	20050201		

IT **185039-47-8 185039-56-9 214983-08-1**
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(diagnostic and drug screening use of cellular kinases involved in human cytomegalovirus infection and treatment of HCMV infection using kinase inhibitors)

RN 185039-47-8 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 185039-56-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(4-morpholinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 214983-08-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 8-methyl-6-phenyl-2-(4-pyridinylamino)-(9CI) (CA INDEX NAME)



L16 ANSWER 21 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2002:171896 Document No. 136:232316 7-Oxopyridopyrimidines as inhibitors of cellular proliferation, and particularly as inhibitors of p38 kinase, for treatment of p38-related conditions. Chen, Jian Jeffrey; Dunn, James Patrick; Goldstein, David Michael; Lim, Julie Anne (F. Hoffmann-La Roche Ag, Switz.). PCT Int. Appl. WO 2002018380 A1 20020307, 135 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-EP9689 20010822. PRIORITY: US 2000-PV229584 20000831.

dioxaspiro[4.5]dec-8-ylamino)-8-methyl- (9CI) (CA INDEX NAME)



IT **402740-32-3P 402740-62-9P 402925-68-2P**
402925-69-3P 402925-70-6P 402925-71-7P
402925-72-8P 402925-73-9P 402925-74-0P
402925-76-2P 402925-77-3P 402925-78-4P
402925-79-5P 402925-81-9P 402925-83-1P
402925-85-3P 402925-86-4P 402925-90-0P
402925-91-1P 402925-92-2P 402925-94-4P
402925-99-9P 402926-00-5P 402926-02-7P
402926-04-9P 402926-07-2P 402926-09-4P
402926-10-7P 402926-17-4P 402926-19-6P
402926-24-3P 402926-26-5P 402926-28-7P
402926-29-8P 402926-30-1P 402926-34-5P
402926-35-6P 402926-39-0P 402926-41-4P
402926-46-9P 402926-47-0P 402926-48-1P
402926-55-0P 402926-56-1P 402926-57-2P
402926-61-8P 402926-62-9P 402926-63-0P
402926-64-1P 402926-65-2P 402926-72-1P
402926-73-2P 402926-74-3P 402926-75-4P
402926-76-5P 402926-77-6P 402926-80-1P
402926-81-2P 402926-83-4P 402926-84-5P
402926-87-8P 402926-88-9P 402926-90-3P
402926-91-4P 402926-92-5P 402926-93-6P
402926-95-8P 402926-96-9P 402927-12-2P
402927-19-9P 402927-20-2P 402927-21-3P
402927-25-7P 402927-29-1P 402927-30-4P
402927-31-5P 402927-34-8P 402927-36-0P
402927-40-6P 402927-42-8P 402927-43-9P
402927-48-4P 402927-49-5P 402927-51-9P
402927-52-0P 402927-63-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of oxopyridopyrimidines as p38 kinase inhibitors)

RN 402740-32-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[(2-hydroxy-1,1-dimethylethyl)amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-70-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[1-(hydroxymethyl)cyclohexyl]amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-71-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[trans-4-(formyloxy)cyclohexyl]amino]-8-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 402925-72-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-[[trans-4-(acetyloxy)cyclohexyl]amino]-6-(2-chlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 402925-73-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-(1,4-dioxaspiro[4.5]dec-8-ylamino)-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-74-0 CAPLUS
CN Carbonic acid, trans-4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]cyclohexyl methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 402925-76-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-(1,5-

dioxaspiro[5.5]undec-9-ylamino)-8-methyl- (9CI) (CA INDEX NAME)



RN 402925-77-3 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-78-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(4-oxocyclohexyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-79-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-81-9 CAPLUS
CN 1-Piperidineacetamide, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-83-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[3-(hydroxymethyl)-3-methyl-1,5-dioxaspiro[5.5]undec-9-yl]amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-85-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[3-(hydroxymethyl)-1,5-dioxaspiro[5.5]undec-9-yl]amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-86-4 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-90-0 CAPLUS
CN 1-Piperidinecarboxaldehyde, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX

NAME)



● HCl

RN 402925-91-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[4-(hydroxymethyl)cyclohexyl]amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-92-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[(4-hydroxycyclohexyl)methyl]amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-94-4 CAPLUS

CN 1-Piperidineacetonitrile, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402925-99-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[4-(hydroxyimino)cyclohexyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 402926-00-5 CAPLUS
CN 1,3-Diazaspiro[4.5]decane-2,4-dione, 8-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-02-7 CAPLUS
CN 1-Piperidineacetic acid, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-04-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-(4-piperidinylamino)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 402926-07-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-[[trans-4-[(aminocarbonyl)oxy]cyclohexyl]amino]-6-(2-chlorophenyl)-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 402926-09-4 CAPLUS
CN Methanesulfonamide, N-[trans-4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]cyclohexyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 402926-10-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-[(trans-4-aminocyclohexyl)amino]-6-(2-chlorophenyl)-8-methyl-, dihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 402740-62-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[2-[2-(ethylthio)ethyl]-1-aziridinyl]-8-methyl- (9CI) (CA INDEX NAME)



RN 402925-68-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[(trans-4-hydroxycyclohexyl)amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 402925-69-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[1-(hydroxymethyl)cyclopentyl]amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018380	A1	20020307	WO 2001-EP9689	20010822
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2420286	AA	20020307	CA 2001-2420286	20010822
	AU 2001093784	A5	20020313	AU 2001-93784	20010822
	EP 1315726	A1	20030604	EP 2001-974206	20010822
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001013628	A	20030701	BR 2001-13628	20010822
	JP 2004507541	T2	20040311	JP 2002-523895	20010822
	US 2002055513	A1	20020509	US 2001-943338	20010830
	US 6518276	B2	20030211		
	US 2002137756	A1	20020926	US 2001-943407	20010830
	US 6506749	B2	20030114		
	US 2003153586	A1	20030814	US 2002-230723	20020829
	US 6861423	B2	20050301		
	US 2003144307	A1	20030731	US 2002-315633	20021210
	US 6753427	B2	20040622		
	ZA 2003001079	A	20040507	ZA 2003-1079	20030207
	US 2004192709	A1	20040930	US 2004-816554	20040401

IT **402928-12-5P**
RL: BYP (Byproduct); PREP (Preparation)
(byproduct; preparation of oxopyridopyrimidines as p38 kinase inhibitors)
RN 402928-12-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[(trans-4-methoxycyclohexyl)amino]-8-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **402927-35-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of oxopyridopyrimidines as p38 kinase inhibitors)
RN 402927-35-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-(1,4-



● 2 HCl

RN 402926-17-4 CAPLUS
CN Sulfamide, N'-[trans-4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]cyclohexyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 402926-19-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, ethyl ester, monohydrochloride . (9CI) (CA INDEX NAME)



● HCl

RN 402926-24-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[(trans-4-methoxycyclohexyl)amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 402926-26-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[1-(2-hydroxyethyl)-4-piperidinyl]amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-28-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[[1-[2-(methylsulfonyl)ethyl]-4-piperidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-29-8 CAPLUS
CN 4-Piperidinamine, 1-acetyl-N-[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-30-1 CAPLUS
CN 4-Piperidinamine, N-[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-

oxopyrido[2,3-d]pyrimidin-2-yl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-34-5 CAPLUS
CN 1-Piperidinesulfonamide, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-35-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-39-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-41-4 CAPLUS
CN 1-Piperidineacetamide, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-46-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[(cis-4-hydroxycyclohexyl)amino]-8-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 402926-47-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[(trans-4-hydroxy-4-methylcyclohexyl)amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 402926-48-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[(cis-4-hydroxy-4-methylcyclohexyl)amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 402926-55-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-(1-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 402926-56-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-(4-morpholinylamino)- (9CI) (CA INDEX NAME)



RN 402926-57-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(4-methyl-1-piperazinyl)amino]- (9CI) (CA INDEX NAME)



RN 402926-61-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(tetrahydro-2H-thiopyran-4-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-62-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[[1-(2,2,2-trifluoroethyl)-4-piperidinyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-63-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(tetrahydro-1-oxido-2H-thiopyran-4-yl)amino]- (9CI) (CA INDEX NAME)



RN 402926-64-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]- (9CI) (CA INDEX NAME)



RN 402926-65-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-72-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[(3S)-hexahydro-2-oxo-1H-azepin-3-yl]amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 402926-73-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-74-3 CAPLUS
CN 4-Piperidinamine, N-[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-1-(propylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-75-4 CAPLUS
CN 4-Piperidinamine, N-[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-1-[(trifluoromethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-76-5 CAPLUS
CN 4-Piperidinamine, N-[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-1-[(2,2,2-trifluoroethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-77-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(tetrahydro-1,1-dioxido-3-thienyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-80-1 CAPLUS
CN 4-Piperidinamine, N-[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-1-[(1-methylethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-81-2 CAPLUS
CN 4-Piperidinamine, N-[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-1-(ethylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-83-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-fluorophenyl)-8-methyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-84-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[4-(2-hydroxyethyl)-1-piperazinyl]amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-87-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[[(3R)-tetrahydro-3-furanyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 402926-88-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[[(3S)-tetrahydro-3-furanyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 402926-90-3 CAPLUS
CN 4-Piperidinamine, N-[6-(2-fluorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-1-(methylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-91-4 CAPLUS
CN 4-Piperidinamine, 1-(ethylsulfonyl)-N-[6-(2-fluorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-92-5 CAPLUS
CN 4-Piperidinamine, N-[6-(2-fluorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-1-[(1-methylethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-93-6 CAPLUS
CN 4-Piperidinamine, N-[6-(2-fluorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-1-(propylsulfonyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-95-8 CAPLUS
CN 4-Piperidinamine, N-[6-(2-fluorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-1-[(trifluoromethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402926-96-9 CAPLUS
CN 4-Piperidinamine, N-[6-(2-fluorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]-1-[(2,2,2-trifluoroethyl)sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402927-12-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-ethyl-2-[(tetrahydro-2H-pyran-4-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402927-19-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-ethyl-2-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402927-20-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[(3-hydroxy-1-methylpropyl)amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402927-21-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[3-(ethylsulfonyl)-1-methylpropyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 402927-25-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(4-

oxocyclohexyl)amino]- (9CI) (CA INDEX NAME)



RN 402927-29-1 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-[(trans-4-aminocyclohexyl)amino]-6-(2-chlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 402927-30-4 CAPLUS
CN Methanesulfonamide, N-[trans-4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 402927-31-5 CAPLUS
CN Sulfamide, N'-[trans-4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]cyclohexyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 402927-34-8 CAPLUS
CN Carbonic acid, trans-4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]cyclohexyl methyl ester (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 402927-36-0 CAPLUS
CN 1-Piperidineacetonitrile, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 402927-40-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[1-(2-hydroxyethyl)-4-piperidinyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 402927-42-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-(4-piperidinylamino)- (9CI) (CA INDEX NAME)



RN 402927-43-9 CAPLUS
CN 1-Piperidinesulfonamide, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 402927-48-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(tetrahydro-2H-thiopyran-4-yl)amino]- (9CI) (CA INDEX NAME)



RN 402927-49-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(tetrahydro-1-oxido-2H-thiopyran-4-yl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402927-51-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]- (9CI) (CA INDEX NAME)



RN 402927-52-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[[(3S)-tetrahydro-3-furanyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402927-63-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[3-(ethylthio)-1-methylpropyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



IT **402927-68-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of oxopyridopyrimidines as p38 kinase inhibitors)
RN 402927-68-8 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[6-(2-chlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



L16 ANSWER 22 OF 61 CAPLUS COPYRIGHT 2005 ACS on STN
2002:171895 Document No. 136:216763 Preparation of 7-oxopyridopyrimidines as p38 MAP kinase inhibitors. Arzeno, Humberto Bartolome; Chen, Jian Jeffrey; Dunn, James Patrick; Goldstein, David Michael; Lim, Julie Anne (F. Hoffmann-La Roche Ag, Switz.). PCT Int. Appl. WO 2002018379 A2 20020307, 64 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-EP9688 20010822. PRIORITY: US 2000-PV229577 20000831.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002018379	A2	20020307	WO 2001-EP9688	20010822
WO 2002018379	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2420122	AA	20020307	CA 2001-2420122	20010822
AU 2002012147	A5	20020313	AU 2002-12147	20010822
EP 1315727	A2	20030604	EP 2001-980258	20010822
EP 1315727	B1	20050629		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 2001013590	A	20030722	BR 2001-13590	20010822
JP 2004507540	T2	20040311	JP 2002-523894	20010822
AT 298751	E	20050715	AT 2001-980258	20010822
US 2002055513	A1	20020509	US 2001-943338	20010830
US 6518276	B2	20030211		
US 2003153586	A1	20030814	US 2002-230723	20020829
US 6861423	B2	20050301		
US 2003144307	A1	20030731	US 2002-315633	20021210
US 6753427	B2	20040622		
ZA 2003001078	A	20040507	ZA 2003-1078	20030207
US 2004192709	A1	20040930	US 2004-816554	20040401

IT **402740-31-2P 402740-32-3P 402740-34-5P 402740-35-6P 402740-36-7P 402740-37-8P 402740-38-9P 402740-39-0P 402740-40-3P 402740-41-4P 402740-42-5P 402740-57-2P 402740-58-3P 402740-59-4P 402740-62-9P 402740-65-2P 402740-66-3P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 7-oxopyridopyrimidines as p38 MAP kinase inhibitors)

RN 402740-31-2 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-8-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402740-32-3 CAPLUS

CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[(2-hydroxy-1,1-dimethylethyl)amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402740-34-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 402740-35-6 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 2-[[1,1-bis(hydroxymethyl)propyl]amino]-6-(2-chlorophenyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 402740-36-7 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino]-8-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402740-37-8 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[(1S)-1-(hydroxymethyl)propyl]amino]-8-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402740-38-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[(1S)-1-(hydroxymethyl)-2,2-dimethylpropyl]amino]-8-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402740-39-0 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-8-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402740-40-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[(1S)-2-hydroxy-1-methylethyl]amino]-8-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402740-41-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[(1S,2S)-1-(hydroxymethyl)-2-methylbutyl]amino]-8-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 402740-42-5 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-8-methyl- (9CI) (CA INDEX NAME)



RN 402740-57-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[[(1S)-2-hydroxy-1,2-dimethylpropyl]amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 402740-58-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-(cyclobutylamino)-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402740-59-4 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-(cyclopentylamino)-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402740-62-9 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[2-[2-(ethylthio)ethyl]-1-aziridinyl]-8-methyl- (9CI) (CA INDEX NAME)



RN 402740-65-2 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-8-methyl-2-[[1-methyl-2-(methylsulfonyl)propyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 402740-66-3 CAPLUS
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[(3-methoxy-1-methylpropyl)amino]-8-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

```
=> file reg
FILE 'REGISTRY' ENTERED AT 16:57:21 ON 19 OCT 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 OCT 2005  HIGHEST RN 865529-02-8
DICTIONARY FILE UPDATES:  18 OCT 2005  HIGHEST RN 865529-02-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************

Structure search iteration limits have been increased.  See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10751703.str
```



chain nodes :
17 18 20 21 23 24 25
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 27
chain bonds :
2-27 8-12 9-17 10-18 11-25 13-20 14-21 15-23 16-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 11-12 11-16 12-13 13-14
14-15 15-16
exact/norm bonds :
2-27 5-7 6-10 7-8 8-9 9-17 9-10 10-18 11-25 13-20 14-21 15-23 16-24
exact bonds :
8-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

G1:H,X

G2:CH3,Et

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 20:CLASS
21:CLASS 23:CLASS 24:CLASS 25:CLASS 27:CLASS

L17 STRUCTURE UPLOADED

=> d his

(FILE 'HOME' ENTERED AT 16:41:45 ON 19 OCT 2005)

FILE 'REGISTRY' ENTERED AT 16:41:56 ON 19 OCT 2005

```
     FILE 'REGISTRY' ENTERED AT 16:44:01 ON 19 OCT 2005
L1              STRUCTURE UPLOADED
L2           16 S L1
L3          314 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 16:45:39 ON 19 OCT 2005
L4           67 S L3
L5            1 S WO-20040063195?/PN
L6           66 S L4 NOT L5
L7            1 S WO-20010044258/PN
L8            1 S L6 AND L7
L9            1 S WO-20030057165?/PN
L10           1 S L6 AND L9
L11           1 S US-5945422/PN
L12           1 S L11 AND L6
L13           2 S US-5733914?/PN
L14           2 S L6 AND L13
L15          61 S L6 NOT L7 NOT L9 NOT L11 NOT L13
L16          61 SORT L15 PY

     FILE 'REGISTRY' ENTERED AT 16:57:21 ON 19 OCT 2005
L17             STRUCTURE UPLOADED

=> s l17 subset = l3 sample
SAMPLE SUBSET SEARCH INITIATED 16:58:00 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -       16 TO ITERATE

100.0% PROCESSED       16 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):          ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):          80 TO      560
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):              0 TO        0

L18           0 SEA SUB=L3 SSS SAM L17

=> s l17 subset = l3 full
FULL SUBSET SEARCH INITIATED 16:58:07 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -      314 TO ITERATE

100.0% PROCESSED      314 ITERATIONS                              3 ANSWERS
SEARCH TIME: 00.00.01

L19           3 SEA SUB=L3 SSS FUL L17

=> d 1-3 ide cbib pi

L19 ANSWER 1 OF 3  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   730979-43-8  REGISTRY
ED   Entered STN:  23 Aug 2004
CN   Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-8-methyl-2-(1-
     piperazinyl)- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   SKI DV 2-103
FS   3D CONCORD
MF   C18 H17 Cl2 N5 O
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 141:157126 Preparation of aminopyridopyrimidinones as tyrosine kinase inhibitors for treatment of cancer.. Veach, Darren R.; Bornmann, William; Clarkson, Bayard D.; Von Bubonoff, Nikolas; Duyster, Justus (Sloan-Kettering Institute for Cancer Research, USA). PCT Int. Appl. WO 2004063195 A1 20040729, 146 pp. DESIGNATED STATES: W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ. (English). CODEN: PIXXD2. APPLICATION: WO 2004-US116 20040105. PRIORITY: US 2003-2003/PV43793U 20030103; US 2003-2003/PV500978 20030908.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004063195	A1	20040729	WO 2004-US116	20040105
	W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GH, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ				
	US 2005009849	A1	20050113	US 2004-751703	20040105

L19 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN
RN 402740-62-9 REGISTRY
ED Entered STN: 25 Mar 2002
CN Pyrido[2,3-d]pyrimidin-7(8H)-one, 6-(2-chlorophenyl)-2-[2-[2-(ethylthio)ethyl]-1-aziridinyl]-8-methyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H21 Cl N4 O S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:232316 7-Oxopyridopyrimidines as inhibitors of cellular proliferation, and particularly as inhibitors of p38 kinase, for treatment of p38-related conditions. Chen, Jian Jeffrey; Dunn, James Patrick; Goldstein, David Michael; Lim, Julie Anne (F. Hoffmann-La Roche Ag, Switz.). PCT Int. Appl. WO 2002018380 A1 20020307, 135 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-EP9689 20010822. PRIORITY: US 2000-PV229584 20000831.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018380	A1	20020307	WO 2001-EP9689	20010822
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2420286	AA	20020307	CA 2001-2420286	20010822
	AU 2001093784	A5	20020313	AU 2001-93784	20010822
	EP 1315726	A1	20030604	EP 2001-974206	20010822
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001013628	A	20030701	BR 2001-13628	20010822
	JP 2004507541	T2	20040311	JP 2002-523895	20010822
	US 2002055513	A1	20020509	US 2001-943338	20010830
	US 6518276	B2	20030211		
	US 2002137756	A1	20020926	US 2001-943407	20010830
	US 6506749	B2	20030114		
	US 2003153586	A1	20030814	US 2002-230723	20020829
	US 6861423	B2	20050301		
	US 2003144307	A1	20030731	US 2002-315633	20021210
	US 6753427	B2	20040622		

ZA 2003001079	A	20040507	ZA 2003-1079	20030207
US 2004192709	A1	20040930	US 2004-816554	20040401

REFERENCE 2: 136:216763 Preparation of 7-oxopyridopyrimidines as p38 MAP kinase inhibitors. Arzeno, Humberto Bartolome; Chen, Jian Jeffrey; Dunn, James Patrick; Goldstein, David Michael; Lim, Julie Anne (F. Hoffmann-La Roche Ag, Switz.). PCT Int. Appl. WO 2002018379 A2 20020307, 64 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2001-EP9688 20010822. PRIORITY: US 2000-PV229577 20000831.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002018379	A2	20020307	WO 2001-EP9688	20010822
WO 2002018379	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2420122	AA	20020307	CA 2001-2420122	20010822
AU 2002012147	A5	20020313	AU 2002-12147	20010822
EP 1315727	A2	20030604	EP 2001-980258	20010822
EP 1315727	B1	20050629		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013590	A	20030722	BR 2001-13590	20010822
JP 2004507540	T2	20040311	JP 2002-523894	20010822
AT 298751	E	20050715	AT 2001-980258	20010822
US 2002055513	A1	20020509	US 2001-943338	20010830
US 6518276	B2	20030211		
US 2003153586	A1	20030814	US 2002-230723	20020829
US 6861423	B2	20050301		
US 2003144307	A1	20030731	US 2002-315633	20021210
US 6753427	B2	20040622		
ZA 2003001078	A	20040507	ZA 2003-1078	20030207
US 2004192709	A1	20040930	US 2004-816554	20040401

L19 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2005 ACS on STN
RN 185039-28-5 REGISTRY
ED Entered STN: 16 Jan 1997
CN 2,5-Pyrrolidinedione, 1-[6-(2,6-dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H12 Cl2 N4 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 128:257440 Preparation of pyrido[2,3-d]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation. Blankley, Clifton John; Boschelli, Diane Harris; Doherty, Annette Marian; Hamby, James Marino; Klutchko, Sylvester; Panek, Robert Lee (Warner-Lambert Company, USA). U.S. US 5733914 A 19980331, 39 pp., Cont.-in-part of U.S. 5,620,981. (English). CODEN: USXXAM. APPLICATION: US 1996-611279 19960403. PRIORITY: US 1995-433294 19950503.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5733914	A	19980331	US 1996-611279	19960403
	US 5620981	A	19970415	US 1995-433294	19950503
	IL 117923	A1	20000601	IL 1996-117923	19960416
	CA 2214219	AA	19961107	CA 1996-2214219	19960426
	WO 9634867	A1	19961107	WO 1996-US5819	19960426
	W: AU, BG, CA, CN, CZ, EE, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9655769	A1	19961121	AU 1996-55769	19960426
	AU 713727	B2	19991209		
	EP 823908	A1	19980218	EP 1996-913175	19960426
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	CN 1183099	A	19980527	CN 1996-193678	19960426
	CN 1083452	B	20020424		
	JP 11504922	T2	19990511	JP 1996-533372	19960426
	NZ 307021	A	20010427	NZ 1996-307021	19960426
	CZ 288160	B6	20010516	CZ 1997-3275	19960426
	EE 3770	B1	20020617	EE 1997-274	19960426
	PL 184093	B1	20020830	PL 1996-323089	19960426
	SK 283952	B6	20040608	SK 1997-1410	19960426
	ZA 9603486	A	19961113	ZA 1996-3486	19960502
	NO 9705033	A	19971031	NO 1997-5033	19971031
	NO 310110	B1	20010521		

REFERENCE 2: 126:59965 Preparation of pyrido[2,3-d]pyrimidines as protein tyrosine kinase mediated cell proliferation inhibitors. Blankley, Clifton John; Boschelli, Diane Harris; Doherty, Annette Marian; Hamby, James Marino; Klutchko, Sylvester; Panek, Robert Lee (Warner-Lambert Company, USA). PCT Int. Appl. WO 9634867 A1 19961107, 147 pp. DESIGNATED STATES: W: AU, BG, CA, CN, CZ, EE, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (English).
CODEN: PIXXD2. APPLICATION: WO 1996-US5819 19960426. PRIORITY: US
1995-433294 19950503; US 1996-611279 19960403.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9634867	A1	19961107	WO 1996-US5819	19960426
	W: AU, BG, CA, CN, CZ, EE, GE, HU, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, UZ, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5620981	A	19970415	US 1995-433294	19950503
	US 5733914	A	19980331	US 1996-611279	19960403
	AU 9655769	A1	19961121	AU 1996-55769	19960426
	AU 713727	B2	19991209		
	EP 823908	A1	19980218	EP 1996-913175	19960426
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
	JP 11504922	T2	19990511	JP 1996-533372	19960426
	NZ 307021	A	20010427	NZ 1996-307021	19960426
	EE 3770	B1	20020617	EE 1997-274	19960426
	PL 184093	B1	20020830	PL 1996-323089	19960426
	SK 283952	B6	20040608	SK 1997-1410	19960426
	NO 9705033	A	19971031	NO 1997-5033	19971031
	NO 310110	B1	20010521		

=>
=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:.
STN INTERNATIONAL LOGOFF AT 17:00:47 ON 19 OCT 2005